NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for HER2-Mutant lung cancer: targeted drug challenges standard chemo
Disease control Recruiting nowThis study tests a new drug, BL-M07D1, against standard chemotherapy for people with a specific type of advanced lung cancer (HER2-mutant non-squamous non-small cell lung cancer) that hasn't been treated yet. About 440 adults will be randomly assigned to receive either the new dr…
Matched conditions: NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New hope for hard-to-treat lung cancer: drug duo targets HER2
Disease control Recruiting nowThis study tests whether a new drug (BL-M07D1) combined with an existing immunotherapy (pembrolizumab) can shrink tumors in people with advanced HER2-positive non-small cell lung cancer. About 80 adults aged 18 to 75 will receive the combination. The goal is to see how many respo…
Matched conditions: NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
Brazilian lung cancer study reveals Real-World treatment gaps
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 adults in Brazil with advanced non-squamous lung cancer whose first chemotherapy stopped working. Researchers want to understand what treatments doctors use next and how patients do. No new treatments are given; the goal is to learn…
Matched conditions: NON-SQUAMOUS NON SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:01 UTC